Search Results - "Rendo, P"

Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects by Valentino, L. A., Rusen, L., Elezovic, I., Smith, L. M., Korth-Bradley, J. M., Rendo, P.

“…Summary Few randomized studies have reported on the use of factor IX (FIX) for secondary prophylaxis in haemophilia B patients. This study aimed to evaluate…”
Get full text

Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B by Kavakli, K., Smith, L., Kuliczkowski, K., Korth-Bradley, J., You, C. W., Fuiman, J., Zupančić-Šalek, S., Abdul Karim, F., Rendo, P.

“…Introduction Limited data are available on optimal prophylaxis regimens of factor IX (FIX) replacements for patients with haemophilia B. Aim This multicentre,…”
Get full text

Clinical experience with moroctocog alfa (AF‐CC) in younger paediatric patients with severe haemophilia A: Two open‐label studies by Rusen, L., Kavakli, K., Korth‐Bradley, J., Huard, F., Rendo, P., Fuiman, J., Baumann, J. A., Smith, L., Alvey, C., Rupon, J.

“…Introduction The pharmacokinetics (PK), efficacy and safety of moroctocog alfa (AF‐CC) have been demonstrated in haemophilia A patients aged ≥6 years. Aim…”
Get full text

Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy by Shafer, F., Smith, L., Vendetti, N., Rendo, P., Carr, M.

“…Summary Spontaneous haemorrhage in patients with haemophilia is generally considered to occur randomly and without a predictable temporal or seasonal pattern;…”
Get full text

Evaluation of the safety and efficacy of recombinant factor IX (nonacog alfa) in minimally treated and previously treated Chinese patients with haemophilia B by Yang, R., Zhao, Y., Wang, X., Sun, J., Jin, J., Wu, D., Charnigo, R., O'Brien, A., Zhong, Z., Rendo, P.

Get full text

A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use by BERNTORP, E., KEELING, D., MAKRIS, M., TAGLIAFERRI, A., MALE, C., MAUSER-BUNSCHOTEN, E. P., MUSSO, R., ROCA, C. A., HASSOUN, A., KOLLMER, C., CHARNIGO, R., BAUMANN, J., RENDO, P.

“…Nonacog alfa, a recombinant factor IX (FIX) used for the treatment of haemophilia B, was approved in Europe in 1998. In accordance with European Medicines…”
Get full text

Decline of high hepatitis C virus prevalence in a hemodialysis unit with no isolation measures during a 6-year follow-up by Valtuille, R, Moretto, H, Lef, L, Rendo, P, Fernández, J L

“…It has been recently suggested that isolation measures may be necessary to avoid hepatitis C virus (HCV) spread in hemodialysis units with a high HCV…”
Get more information

Massive plasmocytosis due to methimazole‐induced bone marrow toxicity by Breier, D.V., Rendo, P., Gonzalez, J., Shilton, G., Stivel, M., Goldztein, S.

“…Pancytopenia is a rare complication of the thionamide therapy reported secondary to aplastic anemia, the bone marrow being invariably hypocellular. We present…”
Get full text

Phase II trial of recombinant interferon-α2b in patients with advanced intractable multidrug-resistant pulmonary tuberculosis: long-term follow-up by PALMERO, D, EIGUCHI, K, RENDO, P, CASTRO ZORRILLA, L, ABBATE, E, GONZALEZ MONTANER, L. J

“…SETTING: Multidrug-resistant tuberculosis patients without human immunodeficiency virus (HIV) infection, with Mycobacterium tuberculosis resistant to almost…”
Get full text

Plasma erythropoietin levels in the oldest old by Musso, C G, Musso, C A F, Joseph, H, De Miguel, R, Rendo, P, Gonzalez, E, Algranati, L, dos Ramos Farias, E

“…Erythropoietin (EPO) regulates erythrocytes production and is synthesized mainly by the kidney. Its production is reduced during chronic renal failure but is…”
Get full text

Evidence of hepatitis C virus passage across dialysis membrane by Valtuille, R, Fernández, J L, Berridi, J, Moretto, H, del Pino, N, Rendo, P, Lef, L

“…The passage of hepatitis C virus (HCV) across the dialysis membrane is a controversial issue. We performed a study applying extreme conditions of permeability…”
Get more information

Influence of hemodialysis procedure on HCV RNA detection in serum and peripheral blood mononuclear cells by Fernández, José Luis, Valtuille, R, Butera, H, Fay, F, Lef, L, Rendo, P

“…To assess whether hemodialysis procedure induces qualitative or quantitative changes in hepatitis C virus (HCV) RNA. We obtained blood samples in the 10 HCV…”
Get more information

The Role of Transfusion-Transmitted Virus in Patients Undergoing Hemodialysis by Valtuille, Rodolfo, Frankel, Fernando, Gómez, Federico, Moretto, Héctor, Fay, Fabián, Rendo, Pablo, Lef, Leonardo, Fernández, José

“…GOALSTo study transfusion-transmitted virus (TTV) infection in 75 patients on hemodialysis and examine its relationship with age, sex, duration of dialysis,…”
Get full text

Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies by Yang, Renchi, Zhao, Yongqiang, Wang, Xuefeng, Sun, Jing, Wu, Runhui, Jin, Chenghao, Jin, Jie, Wu, Depei, Rendo, Pablo, Sun, Feifei, Rupon, Jeremy, Huard, Francois, Korth-Bradley, Joan M, Xu, Lihong, Luo, Binyu, Liu, Yingxue Cathy

“…Moroctocog alfa albumin-free cell culture (AF-CC) increases plasma levels of factor VIII (FVIII) activity and, in China, is indicated for the control and…”
Get full text

Effect of Early Versus Late Administration of Human Recombinant Erythropoietin on Transfusion Requirements in Premature Infants: Results of a Randomized, Placebo-Controlled, Multicenter Trial by Donato, Hugo, Vain, Nestor, Rendo, Pablo, Vivas, Norma, Prudent, Luis, Larguia, Miguel, Digregorio, Jorge, Vecchiarelli, Carmen, Valverde, Regina, Garcia, Cecilia, Subotovsky, Patricia, Solana, Claudio, Gorenstein, Adriana, Private Hospitals Neonatal Network

“…The administration of recombinant human erythropoietin (rHuEPO), started after the first 2 weeks of life, reduces the transfusion requirement in premature…”
Get full text

Erythropoietin and preemies by Donato, Hugo, Rendo, Pablo, Prudent, Luis, Vain, Néstor

Get full text

A double-blind controlled trial of recombinant interferon-α2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels by Fernández, J. L., Rendo, P., del Pino, N., Viola, L.

“…The efficacy and safety of recombinant interferon‐α2b (rIFN‐α2b) was evaluated in a double‐blind controlled trial comprising 23 haemodialysis patients with…”
Get full text

A double-blind controlled trial of recombinant interferon- alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels by Fernandez, J L, Rendo, P, del Pino, N, Viola, L

“…The efficacy and safety of recombinant interferon- alpha 2b (rIFN- alpha 2b) was evaluated in a double-blind controlled trial comprising 23 haemodialysis…”
Get full text

CHANGES ON BODY GROWTH AND EFFECT OF RECOMBINANT HUMAN ERYTHROPOIETIN (rHU EPO). TREATMENT ON RENAL ANEMIA OF CHILDREN WITH END STAGE RENAL DESEASE(ERSD) by Bisigniano, L, Turconi, A, Rendo, P, Escobal, N, Mazza, C

Get full text

Phase II trial of recombinant interferon-alpha2b in patients with advanced intractable multidrug-resistant pulmonary tuberculosis: long-term follow-up by Palmero, D, Eiguchi, K, Rendo, P, Castro Zorrilla, L, Abbate, E, González Montaner, L J

“…Multidrug-resistant tuberculosis patients without human immunodeficiency virus (HIV) infection, with Mycobacterium tuberculosis resistant to almost all of the…”
Get full text